• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Virpax spins off Novvae Pharmaceuticals to develop AnQlar nasal spray

Virpax Pharmaceuticals announced that it has spun off a wholly-owned subsidiary called Novvae Pharmaceuticals that will develop Virpax's over-the-counter products, starting with AnQlar antiviral nasal spray. Virpax acquired North American rights to AnQlar, which contains a mucoadhesive polymer derived from chitosan, from Nanomerics in August 2020 and expanded the deal … [Read more...] about Virpax spins off Novvae Pharmaceuticals to develop AnQlar nasal spray

Evoke Pharma gets notice of allowance for new US patent covering Gimoti metoclopramide nasal spray

According to Evoke Pharma, the company has received a notice of allowance from the US Patent and Trademark Office (USPTO) for patent application No. 17/366,829 ("Nasal Formulations of Metoclopramide"). The patent will cover the composition of Evoke's Gimoti intranasal metoclopramide, which was approved by the FDA in June 2020 for the treatment of diabetic … [Read more...] about Evoke Pharma gets notice of allowance for new US patent covering Gimoti metoclopramide nasal spray

Startup AlveoGene to develop inhaled gene therapies

Oxford Science Enterprises and Harrington Discovery Institute at University Hospitals, together with the University of Edinburgh’s Old College Capital venture investment fund, have created a startup called AlveoGene to develop inhaled gene therapies based on a lentivirus platform technology licensed from the UK Respiratory Gene Therapy Consortium (GTC). The new … [Read more...] about Startup AlveoGene to develop inhaled gene therapies

United Therapeutics files new suit alleging that Liquidia’s Yutrepia treprostinil DPI infringes a patent covering Tyvaso

According to Liquidia Corporation, United Therapeutics has filed a new patent infringement suit in the US District Court for the District of Delaware in response to Liquidia's submission of an sNDA for Yutrepia treprostinil DPI to add pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indication. Yutrepia was tentatively approved … [Read more...] about United Therapeutics files new suit alleging that Liquidia’s Yutrepia treprostinil DPI infringes a patent covering Tyvaso

ENA Respiratory announces new funding, personnel to support Phase 2b study of INNA-051 antiviral nasal spray

ENA Respiratory announced preparations for a Phase 2b study of its INNA-051 pegylated TLR2/6 agonist nasal spray for the prevention of respiratory viruses in people aged 65 and older will be supported by an additional $3.8 million from the US Department of Defense (DOD) as well as by several new clinical appointments. In January 2023, the company said that it had … [Read more...] about ENA Respiratory announces new funding, personnel to support Phase 2b study of INNA-051 antiviral nasal spray

Orexo gets US patent related to its OX640 intranasal dry powder epinephrine

According to Orexo, the United States Patent and Trademark Office (USPTO) has issued the company US patent No. 11,737,980 ("Pharmaceutical composition for drug delivery") which provides protection for OX640 epinephrine nasal powder. Orexo notes that it also received a European patent covering OX640 in 2022. The company announced Phase 1 results for OX640 in October … [Read more...] about Orexo gets US patent related to its OX640 intranasal dry powder epinephrine

Lupin launches its generic tiotropium bromide DPI in the US

Lupin has launched its generic version of Spiriva HandiHaler tiotropium bromide DPI for the treatment of COPD in the US, the company said. The FDA approved Lupin's ANDA for the tiotropium bromide inhaler in June 2023. The generic of Spiriva HandiHaler was recently approved in Australia and has also been approved in the UK and Canada. Lupin CEO Vinita Gupta … [Read more...] about Lupin launches its generic tiotropium bromide DPI in the US

Impel Pharmaceuticals says that it may need to sell assets or enter bankruptcy

Trudhesa dihydroergotamine (DHE) nasal spray maker Impel Pharmaceuticals (formerly Impel Neuropharma) has filed a document with the US Securities and Exchange Commission stating that it "has concluded that there is substantial doubt about the Company’s ability to continue as a going concern." Earlier this year, Impel announced that it needed to "streamline" and would … [Read more...] about Impel Pharmaceuticals says that it may need to sell assets or enter bankruptcy

Galecto to discontinue development of its GB0139 DPI for the treatment of IPF after Phase 2b trial fails to meet its primary endpoint

Galecto has announced that the Phase 2b GALACTIC-1 of its GB0139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis failed to meet its primary endpoint and, as a result, the company will discontinue development of the DPI. GALACTIC-1 was initiated in February 2019. In March 2021, Galecto announced that it was discontinuing the higher dose … [Read more...] about Galecto to discontinue development of its GB0139 DPI for the treatment of IPF after Phase 2b trial fails to meet its primary endpoint

SPH Sine to use Marinomed solubility enhancement technology for formulation of an OINDP

Marinomed Biotech has announced that its Solv4U unit is working with SPH Sine Pharmaceutical Laboratories to develop an OINDP formulation using Marinomed's Marinosolv solubility enhancement technology. According to Marinomed, a feasibility study has been completed, and the companies expect to jointly seek a patent for the Marinosolv formulation. The announcement does … [Read more...] about SPH Sine to use Marinomed solubility enhancement technology for formulation of an OINDP

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews